Bioatla Inc (BCAB) Stock Analysis

Bioatla Inc (BCAB) is a publicly traded company in the HEALTHCARE sector. It trades at $3.53, carries a market capitalization of $6.51M. This page summarizes the public market data, fundamentals, and frequently asked questions for BCAB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.53
• Market Cap: $6.51M
• EPS: $-41.56
• 52-Week High: $71.50
• 52-Week Low: $3.26

Market Sentiment

Bioatla Inc currently has a Neutral sentiment score of 0.12.

About Bioatla Inc

BioAtla, Inc. is a cutting-edge biopharmaceutical firm headquartered in San Diego, California, dedicated to advancing antibody-based therapies for various cancer indications. Leveraging its proprietary Bispecific T cell Engager (BiTEx™) technology, BioAtla is at the forefront of developing innovative treatments designed to selectively target and eradicate cancer cells while preserving healthy tissue. With a strong commitment to addressing critical unmet needs in oncology, the company boasts a...

GNG Research Analysis

GNG Research scores Bioatla Inc (BCAB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BCAB.

Frequently Asked Questions

Does BCAB pay dividends?

Bioatla Inc (BCAB) does not currently pay a regular dividend.

What is BCAB's market cap?

Bioatla Inc (BCAB) has a market capitalization of $6.51M with a current stock price of $3.53.